Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Provention Bio
Thumbnail
August 02, 2021

US FDA approval tracker: July 2021

Thumbnail
July 07, 2021

Big pharma leads the way in stock market resurgence

And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.

Article image
Vantage logo
June 30, 2021

Go or no go? Ardelyx and Chemocentryx among those waiting FDA decisions

Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.

Article image
Vantage logo
June 02, 2021

US FDA approval tracker: May 2021

Article image
Vantage logo
May 28, 2021

Provention’s diabetes project takes a tentative step forward

Article image
Vantage logo
May 05, 2021

US FDA approval tracker: April 2021

Article image
Vantage logo
April 30, 2021

Go or no go? Apellis and Heron head for the finish line

May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.

Article image
Vantage logo
April 09, 2021

Delays look like the best-case scenario for teplizumab

Picking up the Lilly cast-off might not have been an easy win for Provention after all.

Article image
Vantage logo
March 20, 2020

Clinical trial delays become reality as Covid-19 risk spreads

A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.

Article image
Vantage logo
February 27, 2020

Takeda shows it’s serious about coeliac disease

Article image
Vantage logo
September 13, 2019

Upcoming events – Reneuron’s conference data and Provention takes on Crohn’s

Reneuron is set to release further data with its hRPC stem cell therapy in retinitis pigmentosa, while Provention Bio aims to target Crohn’s early with PRV-6527.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 28, 2022

Access valuable insights on payer behaviour

July 18, 2022

Medtech - Going steady

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.